The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...
Following a major push by the industry’s heavyweights to simplify their businesses in recent years, Tanabe Pharma is | While ...
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...
Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips.
Heidi, an “AI Care Partner” that helps clinicians save time and reduce burn out through an array of AI tools, is laying out a unique set of desirable "side effects" in a new brand campaign that puts a ...
The tables have turned for the U.S. biosimilars market. With more than a decade since the first FDA biosim approval, strong launches to biologic copies to AbbVie’s Humira, J&J’s Stelara and ...
Amgen has issued a voluntary recall for nearly 1 million bottles of the heart medication Corlanor (ivabradine) due to possible contamination. The nationwide recall was issued by the company on June 4 ...
Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the ...
Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares, are among the ...
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. | AstraZeneca has impressed ...
Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results